Veligrotug's June 2026 PDUFA decision will determine whether Viridian captures first-mover advantage in TED before Tepezza's competitive moat hardens further

Bull

An FDA approval of veligrotug on or before June 30, 2026 would grant Viridian its first approved product and an immediate commercial foothold in TED, a market currently monopolized by Tepezza (teprotumumab). Given veligrotug's Breakthrough Therapy designation and the Priority Review, approval would validate the differentiated profile — including a more convenient subcutaneous administration route versus Tepezza's IV infusion — and position Viridian to capture meaningful market share before elegrobart's potential approval adds a second commercial asset.

Bear

The most likely negative outcome is a Complete Response Letter citing manufacturing, clinical, or labeling deficiencies, which would delay market entry and allow Tepezza to deepen physician and payer relationships further. A label with restrictive safety language, narrow patient population, or a required REMS could blunt commercial uptake even if approval is technically granted; the recent stock decline on Amgen's Tepezza data also signals that the market is reassessing the competitive headroom veligrotug needs to justify its launch investment.